By a News Reporter-Staff News Editor at Drug Week Aeterna Zentaris Inc. will announce its fourth quarter and full-year 2016 financial and operating results after market close on Wednesday, March 15, 2017. The Company will host a conference call and webcast to discuss these results on Thursday, March 16, 2017 at 8:30 a.m. Eastern Time. About Aeter
At present, new drugs are often launched in China years after they are available in other countries. China is the worlds second-largest drug market but one where foreign firms have struggled with regulations on new products, according to the U.S. International Trade Administration. In addition, foreign manufacturers would not have to undertake...
THOUSAND OAKS- The European Commission has approved Amgen's AMGEVITA as a biosimilar to Humira for the treatment of certain inflammatory diseases. AMGEVITA is Amgen's first biosimilar to be approved by the European Commission. AMGEVITA was approved in the United States by the FDA last September.
By a News Reporter-Staff News Editor at Drug Week Sobi, a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families, announced that the FDA approved a supplemental new drug application for Orfadin capsules in the U.S. The sNDA will allow
OSAKA, Japan& FLORHAM PARK, N.J.& STAMFORD, Conn. Shionogi Inc. and Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration approved Symproic 0.2 mg tablets C-II as a once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation in adult patients with chron
SOUTH SAN FRANCISCO- Genentech, a member of the Roche Group, announced Friday that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation status to Rituxan for pemphigus vulgaris. Genentech is currently enrolling a Phase III study in pemphigus vulgaris, a disease for which there are limited treatment options.
By a News Reporter-Staff News Editor at Drug Week Hutchison China Meditech Limited. London: Friday, March 3, 2017: Hutchison China MediTech Limited announces top-line results from FRESCO, its Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic colorectal cancer in China, who failed at least two
NEW YORK CITY- Merck KgaA and Pfizer Inc. announced that the US Food and Drug Administration has approved BAVENCIO or avelumab Injection 20 mg/mL, for intravenous use, for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma or mMCC. BAVENCIO will be co-commercialized by EMD Serono, the biopharmace
By a News Reporter-Staff News Editor at Drug Week- HYPERLINK " http://www.nanobio.com/"\ nNanoBio Corporation announced that it has been awarded a two-year Phase II Small Business Research Innovation grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, for the development of an intranasa
NuGlobal Healthcare, LLC is founded to innovate and revolutionize generic pharmaceutical industry using proprietary niche technologies and decades of value driven pharmaceutical experience to deliver quality drug products focusing patients unmet needs and affordability by de-risking and maximizing investor capital. NuGlobal Healthcare jointly...
By a News Reporter-Staff News Editor at Drug Week A patent by the inventors Tuereli, Akif Emre; Baumstuemmler, Bernd; Ammer, Richard, filed on April 28, 2014, was published online on March 7, 2017, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. Patent number 9585842 is assigned to SALMON PHARMA GMBH.
Pfizer, a pharmaceutical company, issued the following news release:. Pfizer Inc. today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending that TRUMENBA (R) be granted marketing authorization in the European Union for active immunization of individuals 10 years a
PureTech Health plc, an advanced clinical stage biopharmaceutical company, today announced a licensing and equity agreement with Novartis to advance two clinical-stage programs targeting the mechanistic target of rapamycin complex 1 pathway. PureTech Health will develop these new product candidates in an operating subsidiary, resTORbio, with an...
By a News Reporter-Staff News Editor at Insurance Weekly News New research on Cardiovascular Diseases and Conditions- Hypertension is the subject of a report. Our news journalists obtained a quote from the research from the Johns Hopkins University Bloomberg School of Public Health, "We used 2 datasets for our analysis. Our secondary cohort inclu
By a News Reporter-Staff News Editor at Drug Week Current study results on Oncology- Chronic Myeloid Leukemia have been published. According to news reporting originating in Jena, Germany, by NewsRx journalists, research stated, "The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission following frontline nil
The drug was formerly known as BAX930 and was acquired as part of Shires mega-merger with Baxalta. Phase 1 results were posted by Baxalta back in May of 2016, revealing that 15 patients who were treated during the trial had suffered only minor adverse events that were resolved without the need of medication. Todays confirmation from FDA that SHP655
Our news journalists obtained a quote from the research from the University of Pittsburgh, "To compare the approval and coverage decisions for new anticancer drugs between the United States and 4 other countries: the United Kingdom, France, Australia, and Canada. Of 45 anticancer drug indications approved in the United States between January 1, 200
Mirabilis Medical, a Seattle- area developer of advanced medical technology for non-invasive surgery, announced today CE Mark authorization for marketing of the Mirabilis System for treatment of uterine fibroids throughout the European Union. The company simultaneously announced that it had received approval from the US Food and Drug Administrati
Teewinot Life Sciences Corporation's Subsidiary, Full Spectrum Laboratories, Ltd., Announced Today: Grant of an Important U.S. Patent with Broad Claims to Biosynthetic Production of Cannabinoids. By a News Reporter-Staff News Editor at Drug Week- Teewinot Life Sciences Corporation, a global leader in development of cannabinoid-based pharmaceutica
By a News Reporter-Staff News Editor at Drug Week Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, announced it has received approval of the Company's abbreviated new drug application from the U.S. Food and Drug Administration of Clobetasol Propionate Gel, 0.05%. This is Teligent's second approval for 2017, and its th
By a News Reporter-Staff News Editor at Insurance Weekly News- Vertos Medical, a medical device company committed to developing innovative, minimally invasive treatments for lumbar spinal stenosis, has received national coverage for its mild Procedure through a recently approved study under the Centers for Medicare& Medicaid Services' Coverage
By a News Reporter-Staff News Editor at Drug Week Xenetic Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced that M. Scott Maguire, Xenetic's Chief Executive Officer will present at the 29th Annual ROTH
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today reported topline efficacy results from the double-blind, multi-center, vehicle-controlled, parallel-group study designed to evaluate the efficacy, safety, tolerability and systemic exposure of XEN801 for the treatment of moderate to severe facial acne..
Aeglea BioTherapeutics, Inc., a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancers, today announced topline data from a Phase 1 open-label study evaluating the safety and tolerability of its lead product candidate, AEB1102, for patients with Argi